Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Business & Industry
- Merck awarded Australian CRISPR nickase patent for foundational genome-editing technology
- Selumetinib granted orphan designation in Europe for neurofibromatosis type 1
- Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis
- Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million
- Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island
Research & Development
- Researchers artificially generate immune cells integral to creating cancer vaccines
- The medicine of the future against infection and inflammation?
- Compounds in 'monster' radish could help tame cardiovascular disease
- Taking a pill can effectively treat brutal lung disease
- Differences in immune responses due to age, sex, and genetics
- Mushrooms of the Far East hold promise for the anti-cancer therapy
- Innovative technique converts white fat to brown fat
Conferences & Events
- Lyophilization USA Conference 2018
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
- SMi presents the 9th Conference on Biosimilars & Biobetters
Regulatory Affairs
- FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
- FDA approves treatment for two rare types of non-Hodgkin lymphoma
- FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
- FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
- FDA warns of imposters sending consumers fake warning letters